

CIT2-mRuby2; pcIA-venus-SKL in BY4741

а

b

С

CIT2-mRuby2; penDE-venus-SKL in BY4741



CIT2-mRuby2; pcIA-venus-SKI in BY4741

CIT2-mRuby2; penDE-venus-ARL in BY4741

CIT2-mRuby2; pclA-venus-SKL in *Δpex5*

CIT2-mRuby2; penDE-venus-SKL in *Δpex5*





Supplementary Figure 1. *S. cerevisiae* PTS1 tags are necessary to localise pcIA and penDE to peroxisomes. (a) *S. cerevisiae* peroxisomal protein CIT2 with an mRuby2 fluorescence tag co-localises with venus-fluorescence-tagged *pcIA* and *penDE* proteins additionally tagged with the *S. cerevisiae* Peroxisome Targeting Sequence 1 (PTS1) tripeptide SKL at the C-terminus. For this and subsequent parts, the promoter driving expression of *pcIA* and *penDE* with the venus fluorescence tag is the strong constitutive promoter pTDH3. (b) Venus-fluorescence-tagged *pcIA* and *penDE* proteins without the *S. cerevisiae* PTS1 but tagged with the native *P. chrysogenum* PTS1 tripeptides SKI and ARL do not co-localise with mRuby2-tagged CIT2. (c) Plasmids from part (a) transformed into an *S. cerevisiae* strain harbouring a delete of the peroxisomal importer *pex5* prevent peroxisomal localisation of CIT2 and the *S. cerevisiae* PTS1-tagged *pcIA* and *penDE*



Supplementary Figure 2. Optimising ACV yields. Strong, constitutive promoters driving the ACV-producing part of the benzylpenicillin pathway on a low-copy plasmid (Sc.A2) gives higher maximal ACV yields than the same genes under galactose inducible promoters either integrated into a chromosome (Sc.A1) or on a high-copy plasmid (pESC-pcbAB-npgA). Sc.A2 was grown using glucose as the carbon source, while Sc.A1 and pESC-pcbAB-npgA were grown using galactose as the carbon source. Error bars represent standard deviation from three biological replicates.

| pcbAB | npgA | GAL 1 | GAL 2 | GAL 3 | mean GAL | GAL s.d. | Glu 1 | Glu 2 | Glu 3 | mean GLU | Glu s.d. |
|-----------------|--------|----------|----------|-----------|-----------|-----------|--------------|--------------|--------------|----------|----------|
| GAL1 | GAL7 | 502212.0 | 633534.0 | 217523.0 | 451089.7 | 212665.0 | Not detected | Not detected | Not detected | 0.0 | 0.0 |
| GAL1 | TDH3 | 786826.0 | 943928.0 | 391730.0 | 707494.7 | 284518.5 | Not detected | Not detected | Not detected | 0.0 | 0.0 |
| GAL1 | HHF2 | 561543.0 | 649935.0 | 279805.0 | 497094.3 | 193298.4 | Not detected | Not detected | Not detected | 0.0 | 0.0 |
| GAL1 | RPL18B | 545298.0 | 565738.0 | 349162.0 | 486732.7 | 119577.2 | Not detected | Not detected | Not detected | 0.0 | 0.0 |
| RPL18B | GAL1 | 100022.0 | 116057.0 | 51593.0 | 89224.0 | 33561.1 | 56568.0 | 53651.0 | 43446.0 | 51221.7 | 6890.1 |
| RPL18B | PGK1 | 138596.0 | 110451.0 | 58385.0 | 102477.3 | 40695.6 | 197598.0 | 109863.0 | 157372.0 | 154944.3 | 43917.9 |
| RPL18B | CCW12 | 144395.0 | 116449.0 | 59786.0 | 106876.7 | 43109.1 | 211374.0 | 150211.0 | 87174.0 | 149586.3 | 62102.4 |
| RPL18B | ALD6 | 146092.0 | 68694.0 | 56735.0 | 90507.0 | 48508.0 | 131432.0 | 100424.0 | 107881.0 | 113245.7 | 16185.1 |
| TDH3 | PGK1 | 193113.0 | 86218.0 | 103581.0 | 127637.3 | 57364.3 | 404773.0 | 277704.0 | 284469.0 | 322315.3 | 71490.5 |
| TDH3 | CCW12 | 178619.0 | 138064.0 | 73651.0 | 130111.3 | 52934.0 | 361186.0 | 331388.0 | 218401.0 | 303658.3 | 75323.2 |
| TDH3 | ALD6 | 168824.0 | 74255.0 | 60426.0 | 101168.3 | 58998.1 | 369769.0 | 201340.0 | 218023.0 | 263044.0 | 92802.2 |
| HHF2 | PGK1 | 87157.0 | 40076.0 | 36120.0 | 54451.0 | 28393.2 | 56687.0 | 40722.0 | 28941.0 | 42116.7 | 13925.5 |
| HHF2 | CCW12 | 76374.0 | 72364.0 | 46495.0 | 65077.7 | 16217.5 | 34133.0 | 42551.0 | 21065.0 | 32583.0 | 10826.5 |
| HHF2 | ALD6 | 84088.0 | 32408.0 | 24310.0 | 46935.3 | 32428.9 | 65046.0 | 31137.0 | 45320.0 | 47167.7 | 17029.8 |
| ACV Yields | | | | | | | | | | | |
| | | | | | | | mean conc. | | | | |
| Strain | pcbAB | npgA | sugar | reading 1 | reading 2 | reading 3 | (ng/uL) | conc. s.d. | | | |
| Sc.A1 | GAL10 | GAL1 | gal | 26.868 | 20.011 | 17.482 | 21.454 | 4.857 | | | |
| pESC-npgA-pcbAB | GAL10 | GAL1 | gal | 102.938 | 53.643 | 63.204 | 73.262 | 26.142 | | | |
| Sc.A2 | TDH3 | PGK1 | glu | 362.586 | 249.952 | 255.949 | 289.495 | 63.369 | | | |

Supplementary Table 1. LCMS peak areas and yields for ACV for the pcbAB, npgA promoter screen

| Name (X = sample from screened strain) | Area | Name (X = sample from screened strain) | Area | Name (X = sample from screened strain) | Area |
|--|----------|--|----------|--|------|
| Water | | X49 | | X105 | |
| Water | | X50 | | X106 | |
| benzylpenicillin; 10 pg/uL | | X51 | | X107 | |
| benzylpenicillin; 100 pg/uL | 2233 | X52 | | X108 | |
| benzylpenicillin; 1 ng/uL | 18103 | X53 | | X109 | |
| benzylpenicillin; 10 ng/uL | 165306 | X54 | | X110 | |
| Water | 981629 | X55 | | X111 | |
| water | | X50 | 1500 | X112 | |
| X1 | | X57 | 1506 | X113 | |
| <u>X2</u> | | X58 | | X114 | |
| X3 | | X59 | | X115 | |
| X4 V5 | <u> </u> | X60 X61 | <u> </u> | X110 X117 | |
| X5 X6 | | X61 X62 | | X117 X118 | 586 |
| X7 | | X62 X63 | | X110 X119 | 500 |
| X8 | | X64 | | X120 | |
| X9 | | X65 | | X121 | |
| X10 | | X66 | | X122 | |
| X11 | | X67 | | X123 | |
| X12 | 318 | X68 | | X124 | |
| X13 | | X69 | | X125 | |
| X14 | | X70 | | X126 | |
| X15 | | X71 | 385 | X127 | |
| X16 | | X72 | | X128 | |
| X17 | | X73 | 1285 | X129 | |
| X18 | | Х74 | | X130 | |
| X19 | 2761 | X75 | | X131 | |
| X20 | | X76 | 295 | X132 | |
| X21 | 2709 | Х77 | | X133 | |
| X22 | 1062 | X78 | | X134 | |
| X23 | | Х79 | | X135 | |
| X24 | | X80 | 411 | X136 | |
| X25 | | X81 | | X137 | |
| X26 | | X82 | | X138 | 171 |
| X27 | 1292 | X83 | | X139 | |
| X28 | | X84 | 665 | X140 | |
| X29 | | X85 | | X141 | |
| X30 | | X86 | | X142 | |
| X31 | | X87 | | X143 | |
| X32 | <u> </u> | X88 | <u> </u> | X144 | |
| X33 | | 889 | | X145 | |
| X34 | | X90 | 467 | X146 | 692 |
| X35 | | X91 | | X147 | |
| X36 | | 892 | | X148 | 1648 |
| X37 | 527 | X93 | | X149 | |
| X38 | | X94 | | X150 | 1060 |
| X39 | | X95 | | X151 | |
| X40 | <u> </u> | X97 | <u> </u> | X152 | |
| X41 X42 | <u> </u> | X90 | 2102 | X153 | |
| X42 | | X90 | 2193 | X154 | |
| X43 | 359 | X99 | | X155 | |
| X44 | | X100 | <u> </u> | X150 X157 | |
| X45 | <u> </u> | X101 X102 | <u> </u> | X15/ V150 | |
| X40 X47 | <u> </u> | X102 | | X150 Y150 | |
| X48 | | X104 | <u> </u> | X160 | |
| | | A191 | | 1100 | |

Supplementary Table 2. LCMS peak areas and yields for ACV for the pcbAB, npgA promoter screen

Summed nanopore read count data for single assemblies

| | pcbC | pcIA | penDE |
|---------|------|------|-------|
| pGAL1 | 58 | 79 | 25 |
| pGAL7 | 216 | 139 | 33 |
| pTDH3 | 40 | 107 | 33 |
| pCCW12 | 39 | 59 | 42 |
| pPGK1 | 209 | 89 | 32 |
| pHHF2 | 317 | 91 | 52 |
| pRPL18B | 105 | 71 | 39 |
| pALD6 | 190 | 125 | 42 |
| pPSP2 | 103 | 44 | 73 |
| pREV1 | 78 | 67 | 26 |
| TOTAL | 1355 | 871 | 397 |

Summed nanopore read count data for multiegene level assembly

| | pcbC | pcIA | penDE |
|---------|------|------|-------|
| pGAL1 | 16 | 15 | 12 |
| pGAL7 | 19 | 24 | 7 |
| pTDH3 | 12 | 10 | 10 |
| pCCW12 | 17 | 11 | 13 |
| pPGK1 | 7 | 28 | 13 |
| pHHF2 | 17 | 27 | 25 |
| pRPL18B | 21 | 4 | 12 |
| pALD6 | 3 | 3 | 14 |
| pPSP2 | 13 | 5 | 26 |
| pREV1 | 10 | 8 | 3 |
| TOTAL | 135 | 135 | 135 |

Summed Sanger read count data from all 10 benzylpenicillin producers

| | pcbC | pcIA | penDE |
|---------|------|------|-------|
| pGAL1 | 0 | 0 | 0 |
| pGAL7 | 1 | 0 | 0 |
| pTDH3 | 0 | 2 | 2 |
| pCCW12 | 1 | 5 | 0 |
| pPGK1 | 0 | 3 | 2 |
| pHHF2 | 2 | 0 | 2 |
| pRPL18B | 5 | 0 | 1 |
| pALD6 | 0 | 0 | 0 |
| pPSP2 | 1 | 0 | 3 |
| pREV1 | 0 | 0 | 0 |
| TOTAL | 10 | 10 | 10 |

one-sided Fisher's exact test for enrichment of pcIA strong promoters in multigene assemblies vs. benzylpenicillin producers

| assemblies | va. Delizyi | pemenini producer | | | |
|------------|-----------------------------|-------------------|--|--|--|
| | strong | non-strong | | | |
| multigene | 44 | 938 | | | |
| producers | 10 | 0 | | | |
| n < 0.005 | 0.005 (Eicher's exact test) | | | | |

| p < 0.005 | (Fisher's | exact | test) |
|-----------|-----------|-------|-------|
| | | | |

Observed nanopore read count data by promoter category for single assemblies

| | pcbC | pcIA | penDE |
|-----------|------|------|-------|
| Strong | 605 | 346 | 159 |
| Medium | 295 | 196 | 81 |
| Weak | 181 | 111 | 99 |
| Inducible | 274 | 218 | 58 |

Expected nanopore read counts for single assemblies for Chi square test based on promoter proportions used in library construction

| | pcbC | pcIA | penDE |
|-----------|------|------|-------|
| Strong | 542 | 348 | 159 |
| Medium | 271 | 174 | 79 |
| Weak | 271 | 174 | 79 |
| Inducible | 271 | 174 | 79 |

Observed nanopore read count data by promoter category for multigene

| assemblies | | | | | |
|------------|------|------|-------|----|--|
| | pcbC | pcIA | penDE | | |
| Strong | 53 | 76 | | 61 | |
| Medium | 24 | 7 | | 26 | |
| Weak | 23 | 13 | | 29 | |
| Inducible | 35 | 30 | | 19 | |

Expected nanopore read count data by promoter category for multigene assemblies based on single assembly observed distributions

| | pcbC | pcIA | penDE |
|-----------|------|------|-------|
| Strong | 60 | 54 | 54 |
| | | | |
| Medium | 29 | 30 | 28 |
| Weak | 18 | 17 | 34 |
| Inducible | 27 | 34 | 20 |

Observed nanopore read count data by promoter category for producers

| | pcbC | pcIA | penDE |
|-----------|------|------|-------|
| Strong | 3 | 10 | 6 |
| Medium | 5 | 0 | 1 |
| Weak | 1 | 0 | 3 |
| Inducible | 1 | 0 | 0 |

p-values for Pearson's Chi-squared tests comparing single to multigene level assembly, and Fisher's exact test comparing multigene level

| assembly to producer for promo | assembly to producer for promoter category distributions | | | | |
|--------------------------------|--|-----------|----------|--|--|
| | pcbC | pcIA | penDE | | |
| uniform dist vs. single | p < 0.27 | p < 0.27 | p < 0.27 | | |
| single vs. multigene | p < 0.22 | p < 0.22 | p < 0.22 | | |
| multigene vs. producers | p < 0.15 | p < 0.005 | p < 0.52 | | |

Supplementary Table 3. Read counts and statistics for nanopore and Sanger sequencing

| Experiment | Strain name(s) | Background Strain | plasmid(s) |
|------------|-----------------|---------------------|---------------------|
| Fig 1c, 2a | Sc.A1 | BY4741 | - |
| Fig 1c, d | Sc.P1 | Sc.A1 | pAA056 |
| Fig 1c | Sc.P1x | | |
| Fig 2b, 3 | Sc.P2 | Sc.A2 | pAA179 |
| Fig 3 | Sc.P2x | BY4741 | pAA180, pAA171 |
| Fig 3 | Sc.S1 - Sc.S12 | BY4741 | variants of pAA179* |
| Fig S1 | - | BY4741 | pAA210 |
| Fig S1 | - | BY4741 | pAA211 |
| Fig S1 | - | BY4741 | pAA212 |
| Fig S1 | - | BY4741 | pAA213 |
| Fig S1 | - | BY4741 <i>Δpex5</i> | pAA210 |
| Fig S1 | - | BY4741 <i>Δpex5</i> | pAA211 |
| Fig S2 | pESC-npgA-pcbAB | BY4741 | pESC-npgA-pcbAB |
| Fig S2 | Sc.A2 | BY4741 | pAA145 |

| Primers used to create #peex5strain | | | | |
|-------------------------------------|-------------|--|--|--|
| Purpose | Orientation | Sequence | | |
| to amplify and retarget gRNA vector | F | CGTTTCTATTTTGAATACTAaaagtcccattcgccacccg | | |
| to amplify and retarget gRNA vector | R | /5Phos/gttttagagctagaaatagcaagttaaaataaggctag | | |
| Overlap extension PCR 1 | F | GTGAAGGAAATCGCAGCTCC | | |
| Overlap extension PCR 1 | R | AATGCTAATGAATTTGGGCAGTGATGCGAGCTCCGCCGGAAGAGGGTACCGACTTGTCGG | | |
| Overlap extension PCR 2 | F | CCGACAAGTCGGTACCCTCTTCCGGCGGAGCTCGCATCACTGCCCAAATTCATTAGCATT | | |
| Overlap extension PCR 2 | R | CCTCTCTGTATTCGTGAGAGTATC | | |

Supplementary Table 4. Strains and plasmids used in this paper

* same as pAA179, but with promoters driving pcbC, pclA and penDE as specified by Table S12

| Experiment | Molecule of interest | Sugar | Dropouts | Supplements | Volume |
|-------------------|----------------------|------------|-------------------|-------------|--------|
| Fig 1c, d | ACV | galactose | uracil | 5 mM AAA | 30 mL |
| | | | | 5 mM AAA, | |
| Fig 1c, d | benzylpenicillin | glucose | uracil, histidine | 0.25 mM PAA | 30 mL |
| | | galactose/ | | | |
| Fig S2 | ACV | glucose | uracil | 5 mM AAA | 600 μL |
| | | | | 5 mM AAA, | |
| Fia 2b, 3, S3, S4 | benzylpenicillin | alucose | uracil, histidine | 0.25 mM PAA | 600 μL |

AAA = alpha-amino adipic acid (VWR L13924.0 PAA = phenylacetic acid (Sigma P16621)

Supplementary Table 5. ACV and benzylpenicillin production media composition

| of compounds in the penicillin-G pathway | | | | | |
|--|-------------|-------------|-----------------------|--|--|
| Time (minutes) | % Solvent A | % Solvent B | Flow rate (mL/min) | | |
| 0 | 98 | 2 | 0.2 | | |
| 2 | 98 | 2 | 0.2 | | |
| 8 | 35 | 65 | 0.2 | | |
| 8.01 | 5 | 95 | 0.2 | | |
| 9 | 5 | 95 | 0.2 | | |

The LC gradient elution method for the separation of compounds in the penicillin-G pathway

The MS/MS fragment ions used for the measurement of benzylpenicillin and other materials in the pathway

| Analyte | Formula | Precursor ion [M+H]+ | Product ion | Collision energy (eV) |
|------------------|-------------|-------------------------|-------------|--------------------------|
| benzylpenicillin | C16H18N2O4S | 335.106 | 176.0707 | 16 |
| LLD-ACV | C14H25N3O6S | 364.1537 | 144.0655 | 16 |

Supplementary Table 6. LCMS specifications

| Promoter | Category | Relative Expression* |
|----------|-----------|----------------------|
| pTDH3 | Strong | 820 |
| pCCW12 | Strong | 575 |
| pPGK1 | Strong | 291 |
| pHHF2 | Strong | 230 |
| pRPL18B | Medium | 60 |
| pALD6 | Medium | 39 |
| pPSP2 | Weak | 2.2 |
| pREV1 | Weak | 1.7 |
| pGAL1 | Inducible | 1.3 |
| pGAL7 | Inducible | ** |

Supplementary Table 7. Promoters used in first promoter screen to optimise conversion of ACV to benzylpenicillin.

* Based on fold-change expression over background of fluorescent reporter Venus protein under each promoter, cells grown in glucose.

Taken from Lee, M.E., DeLoache, W.C., Cervantes, B. & Dueber, J.E. ACS Synth Biol 4, 975-986 (2015).

** Uncharacterised in the above study, but should be similar to value from pGAL1, as these promoters naturally drive similar levels of expression when uninduced.

| Sample | pcbC | pcIA | penDE | LCMS | pcIA promoter Strength | penDE promoter Strength | Geometric mean of promoter strength pcIA + penDE | [benzylpenicillin] ng/mL |
|--------|---------|--------|--------|------|------------------------------|-------------------------------|--|-----------------------------|
| X19 | pRPL18B | pTDH3 | pCCW12 | 2761 | 820 | 575 | 686.659 | 3.204 |
| X148 | pRPL18B | pTDH3 | pPGK1 | 1648 | 820 | 291 | 488.487 | 1.845 |
| X98 | pRPL18B | pCCW12 | pPGK1 | 2193 | 575 | 291 | 409.054 | 2.505 |
| X80 | pRPL18B | pTDH3 | pGAL1 | 411 | 820 | 1.3 | 32.650 | 0.418 |
| X84 | pRPL18B | pPGK1 | pPGK1 | 665 | 291 | 291 | 291.000 | 0.699 |
| X37 | pRPL18B | pPGK1 | pHHF2 | 527 | 291 | 230 | 258.708 | 0.545 |
| X90 | pRPL18B | pALD6 | pHHF2 | 467 | 39 | 230 | 94.710 | 0.479 |

Supplementary Table 8. Relationship between promoter strength and benzylpenicillin yield in first promoter screen

Carbon source for these experiments is glucose, with promoter strengths that are indicated those for growth in glucose. Blue = strains featured in Figure 2. Red = strains with low penicillin production, not featured in Figure 2.

Single Gene Assemblies

| Reaction | Туре 2 | Туре З | Туре 4 | Pre-assembled Type 1;Type 5;Type 8 | | |
|----------|--------------|--------|--------|------------------------------------|--|--|
| Single 1 | promoter mix | pcbC | tPGK1 | ConLS;ConR1;AmpR-ColE1 | | |
| Single 2 | promoter mix | pcIA | tENO2 | ConL1;ConR2;AmpR-ColE1 | | |
| Single 3 | promoter mix | penDE | tTDH1 | ConL2;ConRE;AmpR-ColE1 | | |

Multigene Assembly

| Managene Assembly | | | | |
|-------------------|----------|----------|-----------------------------------|--|
| Gene 1 | Gene 2 | Gene 3 | Pre-assembled Type 6;Type7;Type 8 | |
| Single 1 | Single 2 | Single 3 | His3;2micron;KanR-ColE1 | |

Supplementary Table 9. Golden Gate Assembly reaction parts for promoter screen to optimise conversion of ACV to benzylpenicillin and for nanopore sequencing

| Promoter | Category | Relative Expression* |
|----------|----------|----------------------|
| pTDH3 | Strong | 820 |
| pCCW12 | Strong | 575 |
| pPGK1 | Strong | 291 |
| pTEF1 | Strong | 230 |
| pHHF1 | Medium | 81 |
| pRPL18B | Medium | 60 |

Supplementary Table 10. Promoters used in second promoter screen to optimise conversion of ACV to benzylpenicillin

* Based on fold-change expression over background of fluorescent reporter Venus protein under each promoter, cells grown in glucose.

Taken from Lee, M.E., DeLoache, W.C., Cervantes, B. & Dueber, J.E. ACS Synth Biol 4, 975-986 (2015).

Single Gene Assemblies

| Reaction | Туре 2 | Туре З | Туре 4 | Pre-assembled Type 1;Type 5;Type 8 |
|-----------|---------|--------|--------|------------------------------------|
| Single 1 | pTDH3 | pcbC | tPGK1 | ConLS;ConR1;AmpR-ColE1 |
| Single 2 | pCCW12 | pcbC | tPGK1 | ConLS;ConR1;AmpR-ColE1 |
| Single 3 | pPGK1 | pcbC | tPGK1 | ConLS;ConR1;AmpR-ColE1 |
| Single 4 | pTEF1 | pcbC | tPGK1 | ConLS;ConR1;AmpR-ColE1 |
| Single 5 | pHHF1 | pcbC | tPGK1 | ConLS;ConR1;AmpR-ColE1 |
| Single 6 | pRPL18B | pcbC | tPGK1 | ConLS;ConR1;AmpR-ColE1 |
| Single 7 | pTDH3 | pclA | tENO2 | ConL1;ConR2;AmpR-ColE1 |
| Single 8 | pCCW12 | pclA | tENO2 | ConL1;ConR2;AmpR-ColE1 |
| Single 9 | pPGK1 | pclA | tENO2 | ConL1;ConR2;AmpR-ColE1 |
| Single 10 | pTEF1 | pclA | tENO2 | ConL1;ConR2;AmpR-ColE1 |
| Single 11 | pHHF1 | pclA | tENO2 | ConL1;ConR2;AmpR-ColE1 |
| Single 12 | pRPL18B | pclA | tENO2 | ConL1;ConR2;AmpR-ColE1 |
| Single 13 | pTDH3 | penDE | tTDH1 | ConL2;ConRE;AmpR-ColE1 |
| Single 14 | pCCW12 | penDE | tTDH1 | ConL2;ConRE;AmpR-ColE1 |
| Single 15 | pPGK1 | penDE | tTDH1 | ConL2;ConRE;AmpR-ColE1 |
| Single 16 | pTEF1 | penDE | tTDH1 | ConL2;ConRE;AmpR-ColE1 |
| Single 17 | pHHF1 | penDE | tTDH1 | ConL2;ConRE;AmpR-ColE1 |
| Single 18 | pRPL18B | penDE | tTDH1 | ConL2;ConRE;AmpR-ColE1 |

| Multigene Assebmly | | | | | | | | |
|------------------------|-------------------------|--------------------------|-----------------------------------|--|--|--|--|--|
| Gene 1 | Gene 2 | Gene 3 | Pre-assembled Type 6;Type7;Type 8 | | | | | |
| Single 1 – Single 6 | Single 7 – Single 12 | Single 13 – Single 18 | His3;2micron;KanR-ColE1 | | | | | |

Supplementary Table 11. Golden Gate Assembly reaction parts for second promoter screen to optimise conversion of ACV to benzylpenicillin

| | | | | pcbC promoter | pcIA promoter | penDE promoter |
|--------|--------|--------|--------|------------------|------------------|-------------------|
| Strain | pcbC | pcIA | penDE | Strength | Strength | Strength |
| Sc.P2 | HHF1 | TEF1 | PGK1 | 81 | 230 | 291 |
| S7 | TDH3 | CCW12 | TEF1 | 820 | 575 | 230 |
| S2 | PGK1 | TDH3 | TEF1 | 291 | 820 | 230 |
| S3 | RPL18B | TEF1 | TEF1 | 60 | 230 | 230 |
| S1 | RPL18B | TEF1 | TEF1 | 60 | 230 | 230 |
| S6 | RPL18B | TDH3 | CCW12 | 60 | 820 | 575 |
| S4 | PGK1 | TEF1 | PGK1 | 291 | 230 | 291 |
| S5 | TEF1 | TDH3 | PGK1 | 230 | 820 | 291 |
| S10 | CCW12 | PGK1 | CCW12 | 575 | 291 | 575 |
| S11 | RPL18B | HHF1 | RPL18B | 60 | 81 | 60 |
| S8 | TEF1 | TDH3 | CCW12 | 230 | 820 | 575 |
| S12 | TDH3 | PGK1 | TEF1 | 820 | 291 | 230 |
| S9 | PGK1 | RPL18B | TEF1 | 291 | 60 | 230 |

Supplementary Table 12. Promoter strengths for strains shown in Figure 3d